Clinical Trial Outcomes
Negative results could impact product development
- Materiality
- high
Moberg Pharma
Moberg Pharma AB is a Swedish pharmaceutical company focused on the development and commercialization of medical products, particularly in the area of dermatology. The company is known for its innovative treatments for nail fungus, with its flagship product MOB-015 receiving approval in multiple European countries. Moberg Pharma operates primarily through strategic partnerships, allowing it to leverage local expertise for marketing and distribution while focusing its resources on research and development. The company aims to expand its market presence in Europe and eventually enter the U.S. market pending further clinical studies and FDA approval.
5
16.14
15.81
| % | |
|---|---|
| Antifungal Treatments | 70% Includes MOB-015 and related products for nail fungus treatment |
| Licensing Agreements | 20% Revenue from partnerships for product distribution |
| Research and Development | 10% R&D services for pharmaceutical development |
Moberg Pharma primarily serves pharmaceutical companies and healthcare providers through its strategic partnerships...
- Pharmaceutical Partnersprimary
Partners who market and distribute MOB-015 in specific regions
- Healthcare Providerssecondary
Providers offering MOB-015 to patients with nail fungus
- End Consumersemerging
Adults using MOB-015 for nail fungus treatment
Moberg Pharma is headquartered in Sweden and has a significant presence in Europe through its partnerships...
- •Headquartered in Sweden with a focus on European markets
- •National approvals in 13 European countries for MOB-015
- •Partnerships in Canada and Israel for product distribution
- •Long-term goal to enter the U.S. market
Moberg Pharma's strategic priorities include expanding its market presence in Europe and preparing for a future U.S...
01
European Market Expansionmedium-term
To establish a strong market presence and drive revenue growth
02
U.S. Market Entrylong-term
To access the largest market for onychomycosis treatments
Moberg Pharma faces several risks typical of the pharmaceutical industry, including regulatory challenges, market...
Regulatory Approval Delays
Could delay market entry and revenue generation
- Materiality
- high
Partnership Disruptions
Could affect distribution and sales
- Materiality
- medium
Development Expense Capitalization
high
Revenue Recognition
medium
Vimian Group
VIMIAN.ST · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Xbrane Biopharma
XBRANE.ST · Health Care
Xbrane Biopharma AB is a biotechnology company specializing in the development of biosimilars, which are follow-up drugs introduced at a lower price after the original drug's patent expires.
Ascelia Pharma
ACE.ST · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
MEDICINOVA INC
MNOV · Pharmaceutical Preparations
MedicNova Inc.
IRLAB Therapeutics
IRLAB-A.ST · Health Care
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.
CorMedix Inc.
CRMD · Pharmaceutical Preparations
: 11/08/2026